Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 5 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

MUSCAT-HF: No clear evidence of cardioprotection with novel SGLT2 inhibitor in HFpEF

28 Aug 2020

The novel and selective SGLT2 inhibitor luseogliflozin does not seem to produce significant reductions in B‐type natriuretic peptide (BNP) concentrations in patients with type 2 diabetes mellitus (T2DM) and heart failure with preserved ejection fraction (HFpEF) as compared with the alpha‐glucosidase inhibitor voglibose, according to data from the open‐label MUSCAT-HF trial.

In total, 169 T2DM patients with HFpEF were randomized to receive luseogliflozin 2.5 mg once daily (n=86) or voglibose 0.2 mg three times daily (n=85) for 12 weeks. Expansion of follow‐up for an additional 12 weeks was continued in patients who agreed.

Three patients did not receive any doses of a study drug and were excluded from all analyses. The safety population included 166 patients, while the efficacy analysis included 165 patients, 83 in the luseogliflozin (mean age, 71.7 years; 66 percent male) and 82 in the voglibose (mean age, 74.6 years; 59 percent male) groups. BNP was used as the index of the therapeutic effect.

The mean systolic blood pressure and heart rate were similar in the luseogliflozin and voglibose groups. At baseline, the median BNP concentration was 63.7 vs 75.1 pg/mL, respectively, and the median NT‐proBNP concentration was 203 vs 200 pg/mL, respectively.

BNP concentrations decreased over time in the luseogliflozin group. At week 12, the change from baseline was –9.0 percent, which was not significantly different compared with voglibose (−1.9 percent; ratio of change, 0.93, 95 percent confidence interval, 0.78–1.10; p=0.26).

Results for safety outcomes followed a similar pattern. All adverse events and exploratory haemodynamic outcomes were similar between the two groups, except for a significantly lower rate of gastrointestinal symptoms (p=0.013) and greater reduction in systolic blood pressure (p=0.036) with luseogliflozin.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 5 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.